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Background: There has been controversy over the diagnostic thresholds of hemoglobin A1c (HbA1c) for diabetes. In
addition, no study has examined the thresholds of glycated albumin (GA) and 1,5-anhydroglucitol (1,5-AG) for
diagnosing diabetes using the presence of diabetic retinopathy (DR). We examined the optimal thresholds of
various glycemic measures for diagnosing diabetes based on the prevalence of DR in community-dwelling Japanese
subjects.
Methods: A total of 2,681 subjects aged 40-79 years underwent a 75-g oral glucose tolerance test, measurement of
HbA1c, GA, and 1,5-AG, and an ophthalmic examination in 2007-2008. The associations of glycemic measures with
DR status were examined cross-sectionally. DR was assessed by an examination of the fundus photograph of each
eye and graded according to the International Clinical Diabetic Retinopathy Disease Severity Scale. We divided the
values of glycemic measures into ten groups on the basis of deciles. The receiver operating characteristic (ROC)
curve analysis was performed to determine the optimal threshold of each glycemic measure for detecting the
presence of DR.
Results: Of the subjects, 52 had DR. The prevalence of DR increased steeply above the ninth decile for fasting
plasma glucose (FPG) (6.2-6.8 mmol/l), for 2-hour postload glucose (PG) (9.2-12.4 mmol/l), for HbA1c (5.9-6.2%
[41-44 mmol/mol]), and for GA (16.2-17.5%), and below the second decile for 1,5-AG (9.6-13.5 μg/mL). The ROC
curve analysis showed that the optimal thresholds for DR were 6.5 mmol/l for FPG, 11.5 mmol/l for 2-hour PG, 6.1%
(43 mmol/mol) for HbA1c, 17.0% for GA, and 12.1 μg/mL for 1,5-AG. The area under the ROC curve (AUC) for 2-hour
PG (0.947) was significantly larger than that for FPG (0.908), GA (0.906), and 1,5-AG (0.881), and was marginally
significantly higher than that for HbA1c (0.919). The AUCs for FPG, HbA1c, GA, and 1,5-AG were not significantly
different.
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Conclusions: Our findings suggest that the FPG and HbA1c thresholds for diagnosing diabetes in the Japanese
population are lower than the current diagnostic criterion, while the 2-hour PG threshold is comparable with the
diagnostic criterion. 2-hour PG had the highest discriminative ability, whereas FPG, HbA1c, GA, and 1,5-AG were
similar in their ability.
Keywords: Diagnostic criteria, Hemoglobin A1c, Glycated albumin, 1,5-anhydroglucitol, Fasting plasma glucose,
2-hour postload glucose, RetinopathyBackground
The International Expert Committee [1,2], the American
Diabetes Association [3], and the World Health Organization
[4] recently proposed the use of hemoglobin A1c (HbA1c)
to diagnose diabetes at a threshold of 6.5% (48 mmol/mol).
This threshold was based primarily on the findings of sev-
eral epidemiological studies in Western populations that in-
vestigated HbA1c levels associated with a higher prevalence
of diabetic retinopathy (DR), the most specific microvascu-
lar complication of diabetes [5-7]. It has been reported that
a higher HbA1c level was significantly associated with DR in
subjects with diabetes [8], and some clinical trials have
demonstrated that lowering HbA1c levels decreased the risk
of microvascular complications, such as DR, in diabetes pa-
tients [9-11]. These findings suggest that HbA1c levels are
intimately related to the risk of DR, and this evidence sup-
ports the use of HbA1c as a diagnostic tool for diabetes.
However, there has been controversy over the diagnostic
threshold of HbA1c. An integrated study of three general
populations has shown that the relation between fasting
plasma glucose (FPG) levels and the prevalence of retinop-
athy was continuous, with no clear threshold [12], whereas
a prospective study of a French population recently revealed
that the optimal threshold of HbA1c for incident retinop-
athy was 6.0%, which is below the current diagnostic criter-
ion [13]. In addition, several cross-sectional studies of Asian
populations, including our previous study, have examined
this issue [14-18], but the optimal HbA1c thresholds have
differed among these investigations. Thus, a reevaluation of
threshold of HbA1c for DR is needed.
Glycated albumin (GA) and 1,5-anhydroglucitol (1,5-
AG) levels, which are serum markers of hyperglycemia,
have also been found to be significantly associated with
microvascular complications [19,20]. There have been a
few studies investigating GA [21-23] and 1,5-AG levels
[24-26] to detect subjects with glucose intolerance de-
fined by glucose levels, but no study has examined the
diagnostic thresholds of these glycemic measures for dia-
betes based on the presence of DR, and it is uncertain
whether GA and 1,5-AG measurements are applicable as
a diagnostic tool for diabetes [27,28]. In addition, in the
general Asian community, there are limited data asses-
sing FPG and 2-hour postload glucose (PG) levels asso-
ciated with the prevalence of DR [14,17,29].The purposes of this study were to determine the
thresholds of FPG, 2-hour PG, HbA1c, GA, and 1,5-AG
for the diagnosis of diabetes based on the prevalence of
DR in a community-dwelling Japanese population, and
to compare the ability of these five glycemic measures to
differentiate subjects with and without DR.
Methods
Study population
A population-based prospective study of cardiovascular
disease and its risk factors has been underway since
1961 in the town of Hisayama, a suburb of the Fukuoka
metropolitan area on Japan’s Kyushu Island. The popula-
tion of the town has been stable for 50 years and was ap-
proximately 8,400 in 2010. The age and occupational
distributions, and nutritional intake of the population
were similar to those of Japan as a whole based on data
from the national census and nutrition survey [30,31]. In
2007 and 2008, a cross-sectional survey for the present
study was performed in the town. A detailed description
of this survey was published previously [30]. There were
a total of 3,835 residents aged 40-79 years based on the
town registry, and 2,957 (participation rate, 77.1%) took
part in a comprehensive assessment, including a 75-g
oral glucose tolerance test (OGTT), the measurement of
HbA1c, and an ophthalmic examination. We excluded
the eight subjects who did not consent to participate in
the study, 46 who had already had breakfast, 35 who
were on insulin therapy, and 156 who refused the
OGTT, leaving a total of 2,712 subjects who completed
both the 75-g OGTT and HbA1c measurement. Among
these, 21 subjects who lacked ophthalmic examination
information and 10 for whom there was no measurement
of GA or 1,5-AG were excluded, and the remaining 2,681
subjects (1,192 men, 1,489 women) were enrolled in the
present study.
Clinical evaluation and laboratory measurements
The study subjects underwent the OGTT between 8:00
and 10:30 A.M. after an overnight fast of at least
12 hours. Blood for the glucose assay was obtained by
venipuncture into tubes containing sodium fluoride at
fasting and at 2-hour postload, and was separated into
plasma and blood cells within 20 min. Plasma glucose
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According to the 1998 World Health Organization criteria
[32], diabetes was defined as FPG ≥7.0 mmol/l or 2-hour
PG ≥11.1 mmol/l or both, or the use of antidiabetic
medications. Those who were diagnosed with diabetes
with or without treatment before the examination were
considered to be cases of known diabetes. Blood sam-
ples were also collected for the determination of HbA1c
levels, hemoglobin (Hb) and serum creatinine concen-
trations. HbA1c levels were measured by latex aggrega-
tion immunoassay (Determiner HbA1C; Kyowa Medex,
Tokyo, Japan). The values for HbA1c were estimated as
a National Glycohemoglobin Standardization Program
(NGSP) equivalent value calculated with the formula:
HbA1c (%) = 1.02 ×HbA1c (Japan Diabetes Society [JDS])
(%) + 0.25% [33]. A portion of each serum specimen was
stored at -80°C for 5 years until it was used for measure-
ment of GA and 1,5-AG in 2012. Serum GA levels were
determined by an enzymatic method using an albumin-
specific proteinase, ketoamine oxidase, and an albumin
assay reagent (Lucica GA-L; Asahi Kasei Pharma, Tokyo,
Japan). Serum 1,5-AG concentrations were measured en-
zymatically (Lana 1,5AG Auto Liquid; Nippon Kayaku,
Tokyo, Japan). Hb concentrations were measured by so-
dium lauryl sulfate-hemoglobin method. Anemia was de-
fined as Hb <13.0 g/dL for men and <12.0 g/dL for
women [34]. Serum creatinine concentrations were mea-
sured enzymatically, and estimated glomerular filtration
rate (eGFR) was calculated using the following new Japanese
equation: eGFR (mL/min/1.73 m2) = 194 × (serum creatinine
[mg/dL])−1.094 × (age [years])−0.287 × (0.739 if female) [35].
Renal failure was defined as an eGFR <30 mL/min/
1.73 m2 (chronic kidney disease stage 4 or 5) [36].
The height and weight were measured with the subject
in light clothes without shoes, and the body mass index
(BMI) (kg/m2) was calculated. Each participant com-
pleted a self-administered questionnaire covering med-
ical history and antidiabetic treatment.
Ophthalmic examination and definition of diabetic
retinopathy
The methods used for the ophthalmic examination have
been described in detail previously [14]. Briefly, each
participant underwent fundus photographs for the as-
sessment of DR. After pupil dilatation with 1.0% tropica-
mide and 10% phenylephrine, fundus photographs (45°)
were taken from both eyes of each participant using a
Topcon digital TRC NW-6SF fundus camera (Topcon
Corporation, Tokyo, Japan). The photographs were taken
in 1-field per eye, centered on the macula. The photo-
graphs were assessed by photographic graders who were
masked to the clinical information. The severity of DR
was classified into 5 categories according to the Inter-
national Clinical Diabetic Retinopathy Disease SeverityScale: no retinopathy (equivalent to the Early Treatment
of Diabetic Retinopathy Study [ETDRS] scale level 10),
mild nonproliferative DR (equivalent to ETDRS level
20), moderate nonproliferative DR (equivalent to ETDRS
levels 35, 43, and 47), severe nonproliferative DR
(equivalent to ETDRS levels 53A-53E), and proliferative
DR (equivalent to ETDRS levels 61 or higher) [37]. The
degree of DR was determined according to the grading
in the worse eye. The presence of DR was defined as the
presence of mild or moderate or severe nonproliferative
DR, or proliferative DR in either eye.
Statistical analysis
The SAS software package version 9.3 (SAS Institute,
Cary, NC) was used to perform all statistical analyses.
We assessed the statistical significance of differences in
the prevalence or mean of each factor among the DR
status groups by using a logistic or linear regression
model, respectively. To analyze FPG, 2-hour PG, HbA1c,
GA, and 1,5-AG levels as categorical variables, these
values were divided into ten groups on the basis of dec-
iles. The receiver operating characteristic (ROC) curve
analysis was performed to determine the optimal thresh-
old of each glycemic measure for detecting the presence
of DR. The optimal threshold was obtained from the
point on the ROC curve closest to the ideal of 100% sen-
sitivity and 100% specificity. The discrimination of each
measure of glycemia for DR was assessed by the area
under the ROC curve (AUC). The difference in the AUC
was estimated using the method of DeLong et al. [38]. A
value of p < 0.05 was considered statistically significant
in all analyses.
Ethical considerations
This study was conducted with the approval of the Kyushu
University Institutional Review Board for Clinical Research,
and written informed consent was obtained from all the
participants.
Results
Of the study participants, 52 (1.9%) had DR. Mild non-
proliferative DR, moderate nonproliferative DR, severe
nonproliferative DR, and proliferative DR were found in
33 (1.2%), 6 (0.2%), 13 (0.5%), and 0 (0%) subjects, re-
spectively. The clinical characteristics of subjects are
shown in Table 1. The mean age of participants was
60 years, and men comprised 44.5% of the group. The
prevalence of diabetes, known diabetes, anemia, and
renal failure was 15.2%, 10.0%, 13.2%, and 0.3%, respect-
ively. The mean values of age, FPG, 2-hour PG, HbA1c,
GA, diabetes duration and BMI, and the frequencies of
men, diabetes, and known diabetes were significantly
higher in the subjects with DR than in those without
DR, and the subjects with DR had significantly lower
Table 1 Clinical characteristics of subjects, 2007-2008
Variable Total No retinopathy Diabetic retinopathy p value
(n = 2,681) (n = 2,629) (n = 52)
Age (years) 60 (10) 60 (10) 67 (9) <0.001
Men (%) 44.5 43.9 75.0 <0.001
Fasting plasma glucose (mmol/l) 5.8 (1.1) 5.7 (1.0) 8.7 (2.5) <0.001
2-hour postload glucose (mmol/l) 7.9 (3.7) 7.7 (3.4) 18.0 (5.3) <0.001
Hemoglobin A1c (%) 5.5 (0.7) 5.5 (0.7) 7.4 (1.4) <0.001
(mmol/mol) 37 (8) 36 (7) 57 (15) <0.001
Glycated albumin (%) 15.2 (2.8) 15.1 (2.4) 22.7 (6.1) <0.001
1,5-anhydroglucitol (μg/mL) 20.2 (8.3) 20.5 (8.1) 7.7 (7.1) <0.001
Diabetic retinopathy (%) 1.9 0 100 >0.99
Diabetes (%) 15.2 13.6 96.2 <0.001
Known diabetes (%) 10.0 8.3 94.2 <0.001
Diabetes duration (years) 9.5 (7.9) 8.3 (7.2) 14.8 (9.0) <0.001
Body mass index (kg/m2) 23.2 (3.4) 23.2 (3.4) 24.7 (3.6) 0.002
Hemoglobin (g/dL) 13.6 (1.4) 13.6 (1.4) 13.9 (1.5) 0.09
Anemia (%) 13.2 13.1 17.3 0.37
eGFR (mL/min/1.73 m2) 72.9 (13.9) 72.9 (13.8) 71.4 (18.6) 0.44
Renal failure (%) 0.3 0.3 0 0.99
eGFR: estimated glomerular filtration rate. All values are given as the mean (standard deviations) or as a percentage.
Diabetes was defined as fasting plasma glucose of ≥7.0 mmol/l, and/or 2-hour postload glucose of ≥11.1 mmol/l, and/or the use of antidiabetic medication.
Known diabetes was defined as those who were diagnosed with diabetes with or without treatment before the examination.
Anemia was defined as hemoglobin <13.0 g/dL for men and <12.0 g/dL for women.
Renal failure was defined as an eGFR <30 mL/min/1.73 m2.
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the frequencies of anemia and renal failure did not differ
between the groups.
Figure 1A shows the prevalence of DR by deciles of
the distribution of FPG, 2-hour PG, HbA1c, and GA
levels. The prevalence of DR was very low in the first
through eighth deciles for each glycemic measure, but
started to increase steeply from the ninth decile for FPG
(6.2-6.8 mmol/l), 2-hour PG (9.2-12.4 mmol/l), HbA1c
(5.9-6.2% [41-44 mmol/mol]), and GA (16.2-17.5%).
Figure 1B demonstrates the prevalence of DR by deciles of
1,5-AG levels. The prevalence of DR increased markedly
below the second decile for 1,5-AG (9.6-13.5 μg/mL),
while there was no apparent increase in the prevalence of
DR between the third and the tenth deciles of 1,5-AG.
The optimal thresholds of each glycemic measure for
detecting prevalent DR using ROC curve analyses are
shown in Table 2. The optimal threshold was 6.5 mmol/l
for FPG, 11.5 mmol/l for 2-hour PG, 6.1% (43 mmol/
mol) for HbA1c, 17.0% for GA, and 12.1 μg/mL for 1,5-
AG. The sensitivity, specificity, positive predictive value,
and negative predictive value of these thresholds were
82.7%, 86.6%, 10.9%, and 99.6% for FPG, 90.4%, 89.3%,
14.3%, and 99.8% for 2-hour PG, 86.5%, 88.8%, 13.3%,
and 99.7% for HbA1c, 86.5%, 89.0%, 13.5%, and 99.7% for
GA, and 78.8%, 85.8%, 9.9%, and 99.5% for 1,5-AG,respectively. Among the five glycemic measures, 2-hour
PG threshold of 11.5 mmol/l had the highest sensitivity,
while 1,5-AG threshold of 12.1 μg/mL showed the low-
est sensitivity. In addition, with the exception of the
thresholds for 2-hour PG and 1,5-AG, the thresholds of
the glycemic measures were not substantially changed
when DR was defined as a moderate or higher level of
retinopathy (6.5 mmol/l for FPG, 13.1 mmol/l for 2-
hour PG, 6.3% [45 mmol/mol] for HbA1c, 17.2% for GA,
and 10.8 μg/mL for 1,5-AG).
To evaluate the ability of each glycemic measure to
identify the presence of DR, we compared the AUC
among glycemic measures (Figure 2). The AUC for 2-
hour PG was 0.947 (95% confidence interval [CI] 0.922-
0.971), which was significantly larger than that for FPG
(0.908 [95% CI 0.866-0.949]; p = 0.01), GA (0.906 [95% CI
0.853-0.960]; p = 0.03), and 1,5-AG (0.881 [95% CI 0.824-
0.937]; p = 0.01), and was marginally significantly higher
than that for HbA1c (0.919 [95% CI 0.878-0.959]; p = 0.07).
The AUC for 1,5-AG was lower than that for other mea-
sures of glycemia, but there was no significant difference
in the AUC among FPG, HbA1c, GA, and 1,5-AG.
Discussion
Using data from a cross-sectional survey in a Japanese
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Figure 1 Prevalence of diabetic retinopathy by deciles of the distribution of fasting plasma glucose, 2-hour postload glucose,
hemoglobin A1c, glycated albumin (A), and 1,5-anhydroglucitol levels (B). FPG: fasting plasma glucose; 2-hour PG: 2-hour postload glucose;
HbA1c: hemoglobin A1c; GA: glycated albumin; 1,5-AG: 1,5-anhydroglucitol.
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6.5 mmol/l for FPG, 11.5 mmol/l for 2-hour PG, 6.1%
(43 mmol/mol) for HbA1c, 17.0% for GA, and 12.1 μg/mL
for 1,5-AG. These results were in accordance with those
from the prevalence analysis of DR by decile levels of
these measures of glycemia. These findings suggest that
the FPG and HbA1c thresholds for diagnosing diabetes in
the Japanese population are lower than the current diag-
nostic criterion, while the 2-hour PG threshold is approxi-
mately 11.1 mmol/l, which is comparable to the diagnostic
criterion. To our knowledge, the present study is the first
report to determine the GA and 1,5-AG thresholds for the
diagnosis of diabetes using the prevalence of DR. Further-
more, 2-hour PG had higher sensitivity and larger AUCthan other glycemic measures, whereas the AUCs for
FPG, HbA1c, GA, and 1,5-AG were not significantly differ-
ent. These findings indicate that 2-hour PG has the high-
est discriminative ability, and measurements of FPG,
HbA1c, GA, and 1,5-AG are similar in their ability.
The HbA1c thresholds for identifying presence of DR
have varied among prior epidemiological studies of
Asian populations, ranging from 6.1% (43 mmol/mol) to
7.0% (53 mmol/mol). In a study in a Singapore popula-
tion, the optimal HbA1c threshold for DR was 6.6-7.0%
(49-53 mmol/mol) [15]. A subanalysis of the DETECT-2,
which included three Asian studies in India, Singapore,
and Japan, showed that an HbA1c of 6.4% (46 mmol/
mol) was the optimal threshold [16]. Similar findings
Table 2 Thresholds of FPG, 2-hour PG, HbA1c, GA, and
1,5-AG levels for detecting diabetic retinopathy
Threshold Sensitivity Specificity PPV NPV
(%) (%) (%) (%)
FPG 6.5 mmol/l 82.7 86.6 10.9 99.6
2-hour PG 11.5 mmol/l 90.4 89.3 14.3 99.8
HbA1c 6.1% (43 mmol/mol) 86.5 88.8 13.3 99.7
GA 17.0% 86.5 89.0 13.5 99.7
1,5-AG 12.1 μg/mL 78.8 85.8 9.9 99.5
FPG: fasting plasma glucose; 2-hour PG: 2-hour postload glucose; HbA1c:
hemoglobin A1c; GA: glycated albumin; 1,5-AG: 1,5-anhydroglucitol; PPV:
positive predictive value; NPV: negative predictive value.
The optimal threshold was defined as the point on the receiver operating






















Figure 2 Comparison of the discriminative ability of fasting plasma g
albumin, and 1,5-anhydroglucitol for detecting the presence of diabe
postload glucose; HbA1c: hemoglobin A1c; GA: glycated albumin; 1,5-AG: 1,
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[46 mmol/mol]) [17]. On the other hand, in the present
study, the prevalence of DR increased precipitously
when HbA1c levels exceeded 5.9-6.2% (41-44 mmol/
mol), and the optimal threshold of HbA1c using the
ROC analysis was 6.1% (43 mmol/mol). Importantly, this
threshold was identical with that from our previous
study in 1998 (NGSP: 6.1% [43 mmol/mol]; JDS: 5.7%)
[14]. Furthermore, in another epidemiological study in a
Japanese population, the ROC analysis indicated that the
highest precision for DR was observed at an HbA1c
value of 6.2% (44 mmol/mol) [18]. These findings sug-
gest that the HbA1c threshold in the Japanese population
was lower than that of other Asians and also lower than
the diagnostic criterion of 6.5% (48 mmol/mol). Al-
though the reason for this difference is unclear, the in-
fluence of race and ethnicity on HbA1c levels may
contribute to this phenomenon. Some epidemiologicalecificity
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Blacks had higher HbA1c levels than non-Hispanic
whites, independent of glucose [39,40]. In our subjects,
the mean of HbA1c levels (5.5% [37 mmol/mol]) was
lower than those in other Asian population studies (6.0-
6.5% [42-48 mmol/mol]) [15-17]. Thus, it is speculated
that there are racial and ethnic differences in HbA1c
levels even among Asians, and this may be the reason
for the lower threshold in our subjects. In addition, the
aldehyde dehydrogenase 2*2 (ALDH2*2) allele, which is
more common in East Asians than in other ethnic
groups, has been identified as a genetic risk factor for in-
cident DR in Japanese subjects with diabetes [41], and
thus, such a genetic difference in susceptibility to DR
might also affect the HbA1c levels associated with inci-
dent DR.
The use of HbA1c measurement to diagnose diabetes
remains somewhat controversial [42]. Recent epidemio-
logical studies have revealed that HbA1c measurement
alone was less sensitive for detecting subjects with dia-
betes compared to the OGTT [43,44]. However, in our
study, the AUCs for HbA1c and FPG were not signifi-
cantly different. This finding indicates that the discrim-
inative ability of HbA1c for diagnosing diabetes was
comparable to that of FPG. Furthermore, HbA1c meas-
urement can be done without fasting or timed samples,
and thus it would be suitable for mass screening in gen-
eral practice. This advantage has implications for the
early identification and treatment of undiagnosed dia-
betes. For these reasons, HbA1c measurement may be an
appropriate tool for detecting undiagnosed diabetes. In
addition, some clinical and population-based studies, in-
cluding our previous study, have shown that elevated
HbA1c levels were independently associated with cardio-
vascular disease [45,46], suggesting that HbA1c is also
useful as a predictor of macrovascular complications.
Therefore, the use of HbA1c to diagnose diabetes will
help to prevent both micro- and macrovascular compli-
cations of diabetes, which are increasingly recognized as
a global health priority.
In the present analysis, although the prevalence of DR
was quite small for GA below 16.2-17.5%, it began to
rise sharply above these levels, and the optimal threshold
of GA using the ROC analysis was 17.0%. Several studies
have examined the use of GA levels for detecting dia-
betes or glucose intolerance, as defined by glucose levels.
In a Japanese population study, the ROC analysis for de-
tecting diabetes identified the GA threshold as 15.5%
[23], while another study of Japanese subjects reported a
GA level of 17.0% as the lower limit of glucose intoler-
ance [21]. A similar threshold of GA was obtained in a
Chinese population study (17.1%) [22]. The thresholds
in these studies were in good agreement with our find-
ings. Together with those of other studies, our findingssuggest that the optimal GA threshold for diagnosing
diabetes is likely to be 17.0%.
There have been a few studies evaluating the optimal
threshold of 1,5-AG for identifying individuals with dia-
betes, as defined by a OGTT. A Japanese population
study showed that 14.0 μg/mL was the best value for de-
tecting subjects with diabetes [24]. Similar findings were
observed among Japanese male workers (14.2 μg/mL)
[26]. In a Chinese study, the mean of 1,5-AG levels was
15.0 μg/mL in subjects with newly diagnosed diabetes
and 11.8 μg/mL in subjects with known diabetes [25].
However, no study showed an optimal threshold of 1,5-
AG using the presence of DR. The present study re-
vealed that the steepest increment in the prevalence of
DR occurred when the 1,5-AG levels fell below 9.6-
13.5 μg/mL, and that 12.1 μg/mL was the optimal 1,5-AG
threshold in the ROC analysis. Further epidemiological
studies are needed to verify our findings.
The FPG of 7.0 mmol/l and the 2-hour PG of
11.1 mmol/l for diagnosing diabetes with the current cri-
terion were also derived mainly from studies in Western
populations [7]. In our study, the optimal threshold for
detecting prevalent DR was 6.5 mmol/l for FPG, and
11.5 mmol/l for 2-hour PG. The 2-hour PG threshold
was compatible with that from our previous report
(11.1 mmol/l) [14] and another study of a Japanese
population (11.0 mmol/l) [29]. Meanwhile, other Asian
population studies have reported that the optimal FPG
threshold for DR was 7.0 mmol/l in a Japanese popula-
tion [29], and 7.2 mmol/l in a Chinese population [17].
These findings are inconsistent with ours. However, a re-
cent meta-analysis in Asian and Western populations
evaluated the relationship of glucose levels with DR and
concluded that the FPG threshold for diagnosing dia-
betes was 6.5 mmol/l [16]. Furthermore, our prior stud-
ies showed that the threshold of FPG for DR was
6.4 mmol/l [14] and that the FPG threshold correspond-
ing to a 2-h PG of 11.1 mmol/l was 6.2 mmol/l [47].
These results were very similar to those of the present
study. Taken together, these findings imply that, in a Japanese
population, the threshold of FPG for diabetes is lower
than the diagnostic criterion of 7.0 mmol/l, while the
threshold of 2-hour PG is 11.1 mmol/l, which is in ac-
cord with the diagnostic criterion.
The present study showed that among the five gly-
cemic measures, 2-hour PG had not only the highest
sensitivity but also the largest AUC to identify the pres-
ence of DR. These results suggest that the performance
and discriminative ability of 2-hour PG for diagnosing
diabetes were superior to those of other glycemic mea-
sures. Oxidative stress is known to be one of the crucial
contributors in the pathogenesis of DR [48]. It has also
been reported that acute hyperglycemia had a more spe-
cific triggering effect on oxidative stress than chronic
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can be considered a better marker of oxidative stress
levels arising from acute hyperglycemia than FPG,
HbA1c, GA, and 1,5-AG values. Furthermore, a pro-
spective study demonstrated that postprandial plasma
glucose was a stronger predictor of the progression of
DR than HbA1c in Japanese subjects with diabetes [51].
Taken together, these findings imply that 2-hour PG
levels may be more strongly associated with DR than
other glycemic measures. This may explain why 2-hour
PG has a high diagnostic accuracy for DR. On the other
hand, the AUCs for GA and 1,5-AG did not significantly
differ from those for FPG and HbA1c, suggesting that
GA and 1,5-AG are acceptable alternatives for the diag-
nosis of diabetes, and these two measures may be par-
ticularly useful for individuals with anemia, renal disease
or hemoglobinopathy, for whom interpretation of HbA1c
values is problematic. However, the 1,5-AG levels had
smaller AUC with lower sensitivity than other glycemic
measures. One possible explanation for this phenomenon
may be that 1,5-AG levels reflect the degree of glycosuria
rather than glucose levels [28], while other glycemic mea-
sures directly indicate the degree of hyperglycemia. In
addition, it has been reported that 1,5-AG levels were in-
fluenced by individual difference in their renal thresholds
for glucose [52]. These facts might be the reason for the
relatively low discriminative ability of 1,5-AG in our study.
The strengths of our study include the population-
based design, high participation rate, and availability of
data to evaluate the five glycemic measures. In addition,
it is noteworthy that the FPG, 2-hour PG, and HbA1c
thresholds in the present study were nearly the same as
those from our previous study [14], suggesting the high
reproducibility of the results in our population. However,
some limitations should also be mentioned. First, our
analyses included subjects with antidiabetic medications.
Hypoglycemic medications could have affected the levels
of glycemia. The optimal thresholds remained substan-
tially unchanged, except for GA, after excluding subjects
who received hypoglycemic medications (FPG: 6.3 mmol/l;
2-hour PG: 11.5 mmol/l; HbA1c: 6.2% [44 mmol/mol];
GA: 20.5%; and 1,5-AG: 12.1 μg/mL). However, the pre-
cision of this finding may be limited, because of the
small number of cases of DR among those not taking
hypoglycemic medications. Second, the values of HbA1c
were not measured by high-performance liquid chro-
matography (HPLC) as used in the Diabetes Control
and Complications Trial, although the method and re-
agent used to measure HbA1c in this study have since
been NGSP-certified. It would be preferable to measure
HbA1c by HPLC to make the results of our study more
comparable to those of other studies. Third, the GA
and 1,5-AG levels were measured in serum conserved
at -80°C for 5 years. However, the stability of GA and1,5-AG measurements in frozen stored serum sample
was preserved [53,54]. Fourth, this study is a cross-
sectional design, which might have affected the thresh-
old values of glycemic measures. Diagnostic thresholds
would ideally be derived from prospective studies that
examine the relationship between measures of glycemia
and incident microvascular complications. Lastly, the
influence of factors that may affect HbA1c levels, such
as anemia, renal failure, and hemoglobinopathy should
be considered. We performed sensitivity analyses ex-
cluding subjects with anemia or renal failure, and the
optimal threshold of HbA1c remained unchanged
(6.1% [43 mmol/mol]). Furthermore, the prevalence of
hemoglobinopathy in Japan was reported to be very low
(0.04%) [55]. Therefore, the influence of this limitation
would have been small.
Conclusions
The present analysis showed that, in a Japanese popula-
tion, the FPG and HbA1c threshold for diagnosing dia-
betes was lower than the current diagnostic criterion,
while the 2-hour PG threshold was consistent with the
diagnostic criterion, and the discriminative ability of 2-
hour PG was superior to other glycemic measures.
These findings suggest that the threshold of 2-hour PG
is 11.1 mmol/l, regardless of race, whereas ethnic-specific
thresholds of FPG and HbA1c may be necessary. This
study also demonstrated the potential applicability of GA
and 1,5-AG measurements as a diagnostic tool for dia-
betes. Further prospective studies are needed to verify
these findings, and investigations of HbA1c levels in the
intermediate range are also required.
Abbreviations
HbA1c: Hemoglobin A1c; DR: Diabetic retinopathy; FPG: Fasting plasma
glucose; GA: Glycated albumin; 1,5-AG: 1,5-anhydroglucitol; PG: Postload
glucose; OGTT: Oral glucose tolerance test; Hb: Hemoglobin; NGSP: National
Glycohemoglobin Standardization Program; JDS: Japan Diabetes Society;
eGFR: Estimated glomerular filtration rate; BMI: Body mass index; ETDRS: Early
Treatment of Diabetic Retinopathy Study; ROC: Receiver operating
characteristic; AUC: Area under the receiver operating characteristic curve;
CI: Confidence interval; HPLC: High-performance liquid chromatography.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NM contributed to the study concept and design, data collection, data
analysis, data interpretation, and drafting of the manuscript. MY contributed
to the data collection, data interpretation, and drafting of the manuscript.
TN, JH, YH, FI, and MF contributed to the data collection and data
interpretation. TH and DK measured the samples and contributed to the
data interpretation. MK, UN, and TK contributed to the data interpretation
and the critical revision of the manuscript for important intellectual content.
YK contributed to the data collection, data interpretation, drafting of the
manuscript, obtained funding, and study supervision. All authors provided
critical review of the draft and approved the final version.
Acknowledgments
The authors thank the staff of the Division of Health and Welfare of
Hisayama for their cooperation in this study.
Mukai et al. Cardiovascular Diabetology 2014, 13:45 Page 9 of 10
http://www.cardiab.com/content/13/1/45This study was supported in part by Grants-in-Aid for Scientific Research on
Innovative Areas (22116010) and for Scientific Research (A) (25253048 and
22240073), (B) (25293428), and (C) (23590797, 23590798, 23500842, 24590796,
24590797, and 25460758) from the Ministry of Education, Culture, Sports,
Science and Technology of Japan, by Health and Labour Sciences Research
Grants of the Ministry of Health, Labour and Welfare of Japan (Comprehen-
sive Research on Life-Style Related Diseases including Cardiovascular Diseases
and Diabetes Mellitus: H22-Junkankitou [Seishuu]-Ippan-005, H23-Junkankitou
[Seishuu]-Ippan-005, H25-Junkankitou [Seishuu]-Ippan-005, H25-Junkankitou
[Seishuu]-Ippan-009, and H25-Junkankitou [Seishuu]-Sitei-022; and
Comprehensive Research on Dementia: H25-Ninchisho-Ippan-004), and by a
research grant from the Japan Diabetes Society.
Author details
1Department of Environmental Medicine, Graduate School of Medical
Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582,
Japan. 2Department of Medicine and Clinical Science, Graduate School of
Medical Sciences, Kyushu University, Fukuoka, Japan. 3Department of
Ophthalmology, Graduate School of Medical Sciences, Kyushu University,
Fukuoka, Japan. 4Department of Clinical Chemistry and Laboratory Medicine,
Kyushu University Hospital, Fukuoka, Japan. 5Department of Internal
Medicine, Kawanishi City Hospital, Hyogo, Japan.
Received: 5 December 2013 Accepted: 12 February 2014
Published: 17 February 2014
References
1. International Expert Committee: International expert committee report on
the role of the A1C assay in the diagnosis of diabetes. Diabetes Care
2009, 32:1327–1334.
2. Gillett MJ: International expert committee report on the role of the A1C
assay in the diagnosis of diabetes: Diabetes Care 2009; 32(7): 1327-1334.
Clin Biochem Rev 2009, 30:197–200.
3. American Diabetes Association: Diagnosis and classification of diabetes
mellitus. Diabetes Care 2010, 33(Suppl 1):S62–S69.
4. World Health Organization: Use of glycated haemoglobin (HbA1c) in the
diagnosis of diabetes mellitus. 2011.
5. McCance DR, Hanson RL, Charles MA, Jacobsson LT, Pettitt DJ, Bennett PH,
Knowler WC: Comparison of tests for glycated haemoglobin and fasting
and two hour plasma glucose concentrations as diagnostic methods for
diabetes. BMJ 1994, 308:1323–1328.
6. Engelgau MM, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ,
Badran A, Sous ES, Ali MA: Comparison of fasting and 2-hour glucose and
HbA1c levels for diagnosing diabetes. Diagnostic criteria and
performance revisited. Diabetes Care 1997, 20:785–791.
7. The Expert Committee on the diagnosis and classification of diabetes
mellitus: Report of the Expert Committee on the diagnosis and
classification of diabetes mellitus. Diabetes Care 1997, 20:1183–1197.
8. Pang C, Jia L, Jiang S, Liu W, Hou X, Zuo Y, Gu H, Bao Y, Wu Q, Xiang K, Gao
X, Jia W: Determination of diabetic retinopathy prevalence and
associated risk factors in Chinese diabetic and pre-diabetic subjects:
Shanghai diabetic complications study. Diabetes Metab Res Rev 2012,
28:276–283.
9. The Diabetes Control and Complications Trial Research Group: The effect of
intensive treatment of diabetes on the development and progression of
long-term complications in insulin-dependent diabetes mellitus. N Engl J
Med 1993, 329:977–986.
10. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose
control with sulphonylureas or insulin compared with conventional
treatment and risk of complications in patients with type 2 diabetes
(UKPDS 33). Lancet 1998, 352:837–853.
11. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R,
Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D,
Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor
H, Thomas A, Weiss D, Hramiak I: Effect of intensive treatment of
hyperglycaemia on microvascular outcomes in type 2 diabetes: an
analysis of the ACCORD randomised trial. Lancet 2010, 376:419–430.
12. Wong TY, Liew G, Tapp RJ, Schmidt MI, Wang JJ, Mitchell P, Klein R, Klein
BE, Zimmet P, Shaw J: Relation between fasting glucose and retinopathy
for diagnosis of diabetes: three population-based cross-sectional studies.
Lancet 2008, 371:736–743.13. Massin P, Lange C, Tichet J, Vol S, Erginay A, Cailleau M, Eschwège E, Balkau
B: Hemoglobin A1c and fasting plasma glucose levels as predictors of
retinopathy at 10 years: the French DESIR study. Arch Ophthalmol 2011,
129:188–195.
14. Miyazaki M, Kubo M, Kiyohara Y, Okubo K, Nakamura H, Fujisawa K, Hata Y,
Tokunaga S, Iida M, Nose Y, Ishibashi T: Comparison of diagnostic
methods for diabetes mellitus based on prevalence of retinopathy in a
Japanese population: the Hisayama Study. Diabetologia 2004,
47:1411–1415.
15. Sabanayagam C, Liew G, Tai ES, Shankar A, Lim SC, Subramaniam T, Wong
TY: Relationship between glycated haemoglobin and microvascular
complications: is there a natural cut-off point for the diagnosis of
diabetes? Diabetologia 2009, 52:1279–1289.
16. Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K:
Glycemic thresholds for diabetes-specific retinopathy: implications for
diagnostic criteria for diabetes. Diabetes Care 2011, 34:145–150.
17. Xin Z, Yuan MX, Li HX, Hua L, Feng JP, Shi J, Zhu XR, Cao X, Yang JK:
Evaluation for fasting and 2-hour glucose and HbA1c for diagnosing
diabetes based on prevalence of retinopathy in a Chinese population.
PLoS One 2012, 7:e40610.
18. Ito C: Evidence for diabetes mellitus criteria in 2010 using HbA1c.
Diabetol Int 2013, 4:9–15.
19. Selvin E, Francis LM, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL,
Steffes MW: Nontraditional markers of glycemia: associations with
microvascular conditions. Diabetes Care 2011, 34:960–967.
20. Kim WJ, Park CY, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, Kim SW, Park
HS, Kim YJ, Song SJ, Ahn HY: Serum 1,5-anhydroglucitol is associated with
diabetic retinopathy in type 2 diabetes. Diabet Med 2012, 29:1184–1190.
21. Tominaga M, Makino H, Yoshino G, Kuwa K, Takei I, Aono Y, Hoshino T,
Umemoto M, Shimatsu A, Sanke T, Kuwashima M, Taminato T, Ono J:
Report of the committee on standardization of laboratory testing
related to diabetes mellitus of the Japan Diabetes Society:
determination of reference intervals of hemoglobin A1C (IFCC) and
glycoalbumin in the Japanese population. J Japan Diab Soc 2006,
49:825–833 (in Japanese).
22. Ma XJ, Pan JM, Bao YQ, Zhou J, Tang JL, Li Q, Xiang KS, Jia WP: Combined
assessment of glycated albumin and fasting plasma glucose improves
the detection of diabetes in Chinese subjects. Clin Exp Pharmacol Physiol
2010, 37:974–979.
23. Furusyo N, Koga T, Ai M, Otokozawa S, Kohzuma T, Ikezaki H, Schaefer EJ,
Hayashi J: Utility of glycated albumin for the diagnosis of diabetes
mellitus in a Japanese population study: results from the Kyushu and
Okinawa Population Study (KOPS). Diabetologia 2011, 54:3028–3036.
24. Yamanouchi T, Akanuma Y, Toyota T, Kuzuya T, Kawai T, Kawazu S, Yoshioka
S, Kanazawa Y, Ohta M, Baba S, Kosaka K: Comparison of
1,5-anhydroglucitol, HbA1c, and fructosamine for detection of diabetes
mellitus. Diabetes 1991, 40:52–57.
25. Robertson DA, Alberti KG, Dowse GK, Zimmet P, Tuomilehto J, Gareeboo H:
Is serum anhydroglucitol an alternative to the oral glucose tolerance test
for diabetes screening? Diabet Med 1993, 10:56–60.
26. Goto M, Yamamoto-Honda R, Shimbo T, Goto A, Terauchi Y, Kanazawa Y,
Noda M: Correlation between baseline serum 1,5-anhydroglucitol levels
and 2-hour post-challenge glucose levels during oral glucose tolerance
tests. Endocr J 2011, 58:13–17.
27. Koga M, Kasayama S: Clinical impact of glycated albumin as another
glycemic control marker. Endocr J 2010, 57:751–762.
28. Kim WJ, Park CY: 1,5-anhydroglucitol in diabetes mellitus. Endocrine 2013,
43:33–40.
29. Ito C, Maeda R, Ishida S, Harada H, Inoue N, Sasaki H: Importance of OGTT
for diagnosing diabetes mellitus based on prevalence and incidence of
retinopathy. Diabetes Res Clin Pract 2000, 49:181–186.
30. Fukuhara M, Arima H, Ninomiya T, Hata J, Hirakawa Y, Doi Y, Yonemoto K,
Mukai N, Nagata M, Ikeda F, Matsumura K, Kitazono T, Kiyohara Y:
White-coat and masked hypertension are associated with carotid
atherosclerosis in a general population: the Hisayama Study. Stroke 2013,
44:1512–1517.
31. Hata J, Ninomiya T, Hirakawa Y, Nagata M, Mukai N, Gotoh S, Fukuhara M,
Ikeda F, Shikata K, Yoshida D, Yonemoto K, Kamouchi M, Kitazono T,
Kiyohara Y: Secular trends in cardiovascular disease and its risk factors in
Japanese: half century data from the Hisayama Study, 1961-2009.
Circulation 2013, 128:1198–1205.
Mukai et al. Cardiovascular Diabetology 2014, 13:45 Page 10 of 10
http://www.cardiab.com/content/13/1/4532. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes
mellitus and its complications. Part 1: diagnosis and classification of
diabetes mellitus provisional report of a WHO consultation. Diabet Med
1998, 15:539–553.
33. Committee on the standardization of diabetes mellitus-related laboratory
testing of Japan Diabetes Society: International clinical harmonization of
glycated hemoglobin in Japan: from Japan Diabetes Society to National
Glycohemoglobin Standardization Program values. J Diabetes Invest 2012,
3:39–40.
34. World Health Organization: Haemoglobin concentrations for the diagnosis
of anaemia and assessment of severity. Vitamin and Mineral Nutrition
Information System. Geneva: World Health Organization; 2011.
35. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino
Y, Yokoyama H, Hishida A: Revised equations for estimated GFR from
serum creatinine in Japan. Am J Kidney Dis 2009, 53:982–992.
36. National Kidney Foundation: K/DOQI clinical practice guidelines for
chronic kidney disease: evaluation, classification, and stratification. Am J
Kidney Dis 2002, 39:S1–S266.
37. Wilkinson CP, Ferris FL III, Klein RE, Lee PP, Agardh CD, Davis M, Dills D,
Kampik A, Pararajasegaram R, Verdaguer JT: Proposed international clinical
diabetic retinopathy and diabetic macular edema disease severity scales.
Ophthalmology 2003, 110:1677–1682.
38. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under
two or more correlated receiver operating characteristic curves: a
nonparametric approach. Biometrics 1988, 44:837–845.
39. Likhari T, Gama R: Glycaemia-independent ethnic differences in HbA1c in
subjects with impaired glucose tolerance. Diabet Med 2009, 26:1068–1069.
40. Davidson MB, Schriger DL: Effect of age and race/ethnicity on HbA1c
levels in people without known diabetes mellitus: implications for the
diagnosis of diabetes. Diabetes Res Clin Pract 2010, 87:415–421.
41. Morita K, Saruwatari J, Miyagawa H, Uchiyashiki Y, Oniki K, Sakata M,
Kajiwara A, Yoshida A, Jinnouchi H, Nakagawa K: Association between
aldehyde dehydrogenase 2 polymorphisms and the incidence of
diabetic retinopathy among Japanese subjects with type 2 diabetes
mellitus. Cardiovasc Diabetol 2013, 12:132.
42. Waugh NR, Shyangdan D, Taylor-Phillips S, Suri G, Hall B: Screening for type
2 diabetes: a short report for the National Screening Committee. Health
Technol Assess 2013, 17:1–90.
43. Kramer CK, Araneta MR, Barrett-Connor E: A1C and diabetes diagnosis: the
Rancho Bernardo study. Diabetes Care 2010, 33:101–103.
44. Hjellestad ID, Astor MC, Nilsen RM, Søfteland E, Jonung T: HbA1c versus oral
glucose tolerance test as a method to diagnose diabetes mellitus in
vascular surgery patients. Cardiovasc Diabetol 2013, 12:79.
45. Penno G, Solini A, Zoppini G, Orsi E, Fondelli C, Zerbini G, Morano S, Cavalot
F, Lamacchia O, Trevisan R, Vedovato M, Pugliese G: Hemoglobin A1c
variability as an independent correlate of cardiovascular disease in
patients with type 2 diabetes: a cross-sectional analysis of the Renal
Insufficiency and Cardiovascular Events (RIACE) Italian multicenter study.
Cardiovasc Diabetol 2013, 12:98.
46. Ikeda F, Doi Y, Ninomiya T, Hirakawa Y, Mukai N, Hata J, Shikata K, Yoshida
D, Matsumoto T, Kitazono T, Kiyohara Y: Haemoglobin A1c even within
non-diabetic level is a predictor of cardiovascular disease in a general
Japanese population: the Hisayama study. Cardiovasc Diabetol 2013,
12:164.
47. Doi Y, Kubo M, Yonemoto K, Ninomiya T, Iwase M, Arima H, Hata J, Tanizaki
Y, Iida M, Kiyohara Y: Fasting plasma glucose cutoff for diagnosis of
diabetes in a Japanese population. J Clin Endocrinol Metab 2008,
93:3425–3429.
48. Madsen-Bouterse SA, Kowluru RA: Oxidative stress and diabetic
retinopathy: pathophysiological mechanisms and treatment
perspectives. Rev Endocr Metab Disord 2008, 9:315–327.
49. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C: Activation
of oxidative stress by acute glucose fluctuations compared with
sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA
2006, 295:1681–1687.
50. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M,
Giugliano D: Oscillating glucose is more deleterious to endothelial
function and oxidative stress than mean glucose in normal and type 2
diabetic patients. Diabetes 2008, 57:1349–1354.
51. Shiraiwa T, Kaneto H, Miyatsuka T, Kato K, Yamamoto K, Kawashima A,
Kanda T, Suzuki M, Imano E, Matsuhisa M, Hori M, Yamasaki Y: Postprandialhyperglycemia is a better predictor of the progression of diabetic
retinopathy than HbA1c in Japanese type 2 diabetic patients. Diabetes
Care 2005, 28:2806–2807.
52. Kilpatrick ES, Keevilt BG, Richmond KL, Newland P, Addison GM: Plasma
1,5-anhydroglucitol concentrations are influenced by variations in the
renal threshold for glucose. Diabet Med 1999, 16:496–499.
53. Nowatzke W, Sarno MJ, Birch NC, Stickle DF, Eden T, Cole TG: Evaluation of
an assay for serum 1,5-anhydroglucitol (GlycoMark™) and determination
of reference intervals on the Hitachi 917 analyzer. Clin Chim Acta 2004,
350:201–209.
54. Nathan DM, Steffes MW, Sun W, Rynders GP, Lachin JM: Determining
stability of stored samples retrospectively: the validation of glycated
albumin. Clin Chem 2011, 57:286–290.
55. Harano T: Hemoglobinopathy in Japan: detection and analysis. Rinsho
Byori 1999, 47:215–223 (in Japanese).
doi:10.1186/1475-2840-13-45
Cite this article as: Mukai et al.: Thresholds of various glycemic
measures for diagnosing diabetes based on prevalence of retinopathy
in community-dwelling Japanese subjects: the Hisayama Study.
Cardiovascular Diabetology):2014 13:45.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
